

June 7, 2016



# **Abeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference**

## **Company CEO to Present on Thursday, June 9th at 4 pm ET**

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 06/07/16 --

Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that CEO and President, Tim Miller, Ph.D., will be presenting for the company at the Jefferies 2016 Healthcare Conference in New York City, Thursday, June 9<sup>th</sup>, 2016 at 4 pm ET.

The following are the specific details regarding Abeona Therapeutics Presentation:

Event: Jefferies 2016 Healthcare Conference

Date: Thursday, June, 9<sup>th</sup>, 2016

Time: 4 pm ET

Location: Grand Hyatt, New York, NY

Room: Imperial

Webcast Link: <http://wsw.com/webcast/jeff97/abeo>

### ***About Jefferies 2016 Healthcare Conference:***

The 2016 Jefferies Healthcare Conference will feature an extensive range of public & private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors. The four day conference will be comprised of company presentations, Q&A breakout sessions and thematic panels. Company management teams and investors will also have the opportunity to participate in 1x1 and small group meetings.

### ***About Abeona :***

Abeona Therapeutics Inc. delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV-NAGLU) and ABO-102 (AAV- SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). The company is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using its proprietary

SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit [www.abeonatherapeutics.com](http://www.abeonatherapeutics.com)

*This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.*

Company and Media Contact:

Andre'a Lucca  
Vice President, Communications & Operations  
Abeona Therapeutics Inc  
+1 (212)-786-6208  
[alucca@abeonatherapeutics.com](mailto:alucca@abeonatherapeutics.com)

Christine Berni-Silverstein  
Vice President, Investor Relations  
Abeona Therapeutics Inc.  
+1 (212)-786-6212  
[csilverstein@abeonatherapeutics.com](mailto:csilverstein@abeonatherapeutics.com)

Source: Abeona Therapeutics